Tarsus Pharmaceuticals (TARS) News Today $44.83 -1.82 (-3.90%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call TranscriptNovember 16 at 2:28 AM | msn.comTarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsNovember 16 at 2:28 AM | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.3% - Here's WhyTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.3% - What's Next?November 15 at 1:13 PM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Given New $41.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday.November 15 at 8:21 AM | marketbeat.comTarsus Pharmaceuticals price target raised to $73 from $61 at H.C. WainwrightNovember 15 at 2:27 AM | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month High Following Analyst UpgradeNovember 15 at 2:05 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business AchievementsNovember 14 at 5:21 PM | finanznachrichten.deTarsus Pharmaceuticals Reports Strong Q3 2024 PerformanceNovember 14 at 12:15 PM | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High on Analyst UpgradeTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High After Analyst UpgradeNovember 14 at 10:12 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $65.00Oppenheimer upped their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research report on Thursday.November 14 at 8:32 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comTarsus Pharmaceuticals (TARS) Gets a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comTarsus Pharmaceuticals appoints Goodrich to board of directorsNovember 13, 2024 | markets.businessinsider.comTarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of DirectorsNovember 13, 2024 | globenewswire.comLisanti Capital Growth LLC Acquires New Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Lisanti Capital Growth LLC bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 39,845 shares of the company's stock, valued at approxNovember 11, 2024 | marketbeat.comTarsus Pharmaceuticals (TARS) Set to Announce Quarterly Earnings on WednesdayTarsus Pharmaceuticals (NASDAQ:TARS) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 8, 2024 | marketbeat.comCreative Planning Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Creative Planning purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,002 shares of the company's stock, valued at approximately $362November 8, 2024 | marketbeat.comTarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024November 6, 2024 | globenewswire.comTarsus Pharmaceuticals seesaws amid report Alcon interest has cooledNovember 6, 2024 | msn.comTarsus Pharmaceuticals appoints Elizabeth Yeu as CMONovember 6, 2024 | markets.businessinsider.comTarsus Pharmaceuticals Appoints New Chief Medical OfficerNovember 6, 2024 | markets.businessinsider.comTarsus Appoints Elizabeth Yeu, M.D., as Chief Medical OfficerNovember 5, 2024 | globenewswire.comEmerald Advisers LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Emerald Advisers LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 146,298 shares of the company's stock, valued at approximately $4,812,000November 4, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by AnalystsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendatioNovember 4, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 8.5% - What's Next?Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 8.5% - Here's What HappenedNovember 1, 2024 | marketbeat.comTarsus Pharmaceuticals rumor highlighted in Betaville blogOctober 30, 2024 | markets.businessinsider.comTarsus Pharmaceuticals management to meet with OppenheimerOctober 29, 2024 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month High - What's Next?Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 1-Year High - Still a Buy?October 29, 2024 | marketbeat.comBarclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)October 28, 2024 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - What's Next?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - Should You Buy?October 28, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Buys 29,465 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Allspring Global Investments Holdings LLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 16.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 210,531 shares of tOctober 28, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $37.54 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Assenagon Asset Management S.A. grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 7.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 1,141,247 shares of the company's stock after acquiring an additional 77October 25, 2024 | marketbeat.comPromising Market Potential and Strategic Growth Drive Buy Rating for Tarsus PharmaceuticalsOctober 18, 2024 | markets.businessinsider.comTarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%October 17, 2024 | globenewswire.comEssex Investment Management Co. LLC Invests $3.59 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Essex Investment Management Co. LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 109,156 shares of the company's stock, valueOctober 13, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issuedOctober 10, 2024 | marketbeat.comTarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...October 9, 2024 | finance.yahoo.comMillennium Management LLC Increases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Millennium Management LLC increased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 1,259.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 348,586 shares of the company's stock after purchasing an adOctober 9, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 17,931 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Dimensional Fund Advisors LP reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 406,899 shares of the company's stock after sOctober 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comHealthcare of Ontario Pension Plan Trust Fund Decreases Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Healthcare of Ontario Pension Plan Trust Fund decreased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 56.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 389,600 shares ofOctober 5, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.3% - Should You Buy?Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 5.3% - Here's WhyOctober 4, 2024 | marketbeat.comDriehaus Capital Management LLC Purchases 203,300 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Driehaus Capital Management LLC boosted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 126.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 364,463 shares of the company's stoSeptember 30, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Reduces Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Frazier Life Sciences Management L.P. trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 11.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,587,527 shares of the company's stock after selling 200,000 shares duriSeptember 29, 2024 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)September 28, 2024 | markets.businessinsider.comTarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024September 25, 2024 | globenewswire.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Ensign Peak Advisors IncEnsign Peak Advisors Inc lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 18.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 594,325 shares of tSeptember 24, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)September 24, 2024 | markets.businessinsider.comTarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care InnovationsSeptember 20, 2024 | seekingalpha.com Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.420.55▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼184▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fusion Pharmaceuticals News MeiraGTx News Elanco Animal Health News Cytokinetics News Blueprint Medicines News Lantheus News Nuvalent News Arcellx News ADMA Biologics News Krystal Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
